NCT06297616View on ClinicalTrials.gov

A Study of LY3841136 in Japanese Participants With Obesity or Overweight

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

128

Participants

Timeline

Start Date

April 15, 2024

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions
ObesityOverweight
Interventions
DRUG

LY3841136

Administered SC

DRUG

LY3841136-Placebo

Administered SC

DRUG

Tirzepatide

Administered SC

DRUG

Tirzepatide-Placebo

Administered SC

Trial Locations (3)

192-0071

P-One Clinic, Hachiōji

130-0004

Sumida Hospital, Sumida-ku

812-0025

Hakata Clinic, Fukuoka

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY